KR100684547B1 - C-myc의 안티센스 표적화에 의한 재협착 치료 방법 - Google Patents
C-myc의 안티센스 표적화에 의한 재협착 치료 방법 Download PDFInfo
- Publication number
- KR100684547B1 KR100684547B1 KR1020017009506A KR20017009506A KR100684547B1 KR 100684547 B1 KR100684547 B1 KR 100684547B1 KR 1020017009506 A KR1020017009506 A KR 1020017009506A KR 20017009506 A KR20017009506 A KR 20017009506A KR 100684547 B1 KR100684547 B1 KR 100684547B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- antisense
- antisense compound
- pharmaceutical composition
- catheter
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
Abstract
Description
Claims (25)
- (i) 한 개의 서브유닛의 모르폴리노 질소를 인접 서브유닛의 5' 환외 탄소에 2 원자 길이로 연결하는, 포스포로디아미데이트 연결에 의해서 서로 연결된 모르폴리노 서브유닛, 및(ii) 서브유닛에 부착되고 SEQ ID NO:1으로 표시된 서열을 포함하는 염기 서열을 갖는 모르폴리노 안티센스 화합물을 포함하는환자에 있어서 재협착 저해에 사용하기 위한 약제학적 조성물.
- 삭제
- 제 1 항에 있어서,(a) 혈관 영역을 안티센스 화합물을 포함하는 저장소와 접촉시키고, 이온도입법 또는 일렉트로포레이션에 의해 저장소로부터 혈관에 화합물을 도입하는 방식;(b) 카테테르 풍선의 표면상에 포함된, 혈관의 중간막을 침투할 수 있는 주입기를 통해 압력하에서, 카테테르로부터 혈관 영역에 화합물을 직접 주입하는 방식;(c) 트랩된 형태로 안티센스 화합물을 포함하는 미세입자를 혈관 영역에 주입하거나 접촉시키는 방식;(d) 혈관 영역을 카테테르 풍선의 표면상에 포함되고, 확산가능한 형태로 안티센스 화합물을 포함하는 히드로겔 코팅과 접촉시키는 방식; 및(e) 혈관 영역을 확산가능한 형태로 안티센스 화합물을 포함하는 외표면층을 가지는 스텐트와 접촉하는 방식으로 구성되는 군으로부터 선택되는 방식으로 투여되는 것을 특징으로 하는 약제학적 조성물.
- 제 4 항에 있어서, 투여된 안티센스 화합물의 양은 0.5 내지 20 mg인 것을 특징으로 하는 약제학적 조성물.
- 제 4 항에 있어서, (a)에 제시된 투여 방식에 있어서, 안티센스 화합물은 카테테르 내의 2 개의 팽창된 풍선 사이의 부피로 함유되고, 화합물은 순 전하를 포함하고, 부피는 혈관 영역에 화합물을 이온도입적으로 송달하기에 효과적인 펄스 전기장에 제공되는 것을 특징으로 하는 약제학적 조성물.
- 제 4 항에 있어서, (a)에 제시된 투여 방식에 있어서, 안티센스 화합물은 카테테르 내의 2 개의 팽창된 풍선 사이의 부피로 함유되고, 부피는 일렉트로포레이션에 의해서 혈관-영역 세포로의 화합물 흡수를 용이하게 하기에 효과적인 펄스 전기장에 제공되는 것을 특징으로 하는 약제학적 조성물.
- 제 4 항에 있어서, (b)에 제시된 투여 방식에 있어서, 카테테르 풍선은 말단-팁 저장소와 연통하는 다수의 외부-접촉 채널을 가지고, 각 채널은 하나 이상의 주입구를 가지고, 이 주입은 풍선이 팽창된 위치에 있을 때, 상기 주입구를 통해 상기 저장소로부터 안티센스 화합물의 용액 또는 현탁액을 밀어넣는 것을 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 4 항에 있어서, (c)에 제시된 투여 방식에 있어서, 카테테르는 원단부 저장소를 가지고, 미세입자는 저장소에 입자 현탁액으로 포함되고, 상기 주입은 혈관 영역과 접촉하여 카테테르 표면을 통해 카테테르로부터 현탁액을 밀어넣는 것을 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 조성물은 미세버블 입자에 트랩된 것을 특징으로 하는 약제학적 조성물.
- 제 4 항에 있어서, (e)에 제시된 투여 방식에 있어서, 스텐트는 생분해성인 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 화합물은 화합물의 5' 말단에 부착된 트리에틸렌글리콜로 유도체화되어 있고, 화합물은 적어도 30 mg/ml의 안티센스 화합물을 포함하는 용액으로부터 투여되는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 화합물은 화합물의 5' 말단에 부착된 트리에틸렌글리콜로 유도체화되어 있는 것을 특징으로 하는 약제학적 조성물.
- 제 1 항에 있어서, 화합물은 리포좀 또는 생분해성 미세입자에 트랩된 것을 특징으로 하는 약제학적 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11784699P | 1999-01-29 | 1999-01-29 | |
US60/117,846 | 1999-01-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010101760A KR20010101760A (ko) | 2001-11-14 |
KR100684547B1 true KR100684547B1 (ko) | 2007-02-20 |
Family
ID=22375152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017009235A KR20010102992A (ko) | 1999-01-29 | 2000-01-28 | 표적 rna를 검출하는 비-침입적 방법 |
KR1020017009506A KR100684547B1 (ko) | 1999-01-29 | 2000-01-29 | C-myc의 안티센스 표적화에 의한 재협착 치료 방법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017009235A KR20010102992A (ko) | 1999-01-29 | 2000-01-28 | 표적 rna를 검출하는 비-침입적 방법 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6365351B1 (ko) |
EP (2) | EP1173561A2 (ko) |
JP (2) | JP2002535015A (ko) |
KR (2) | KR20010102992A (ko) |
AT (1) | ATE445700T1 (ko) |
AU (2) | AU778057B2 (ko) |
CA (2) | CA2360997A1 (ko) |
DE (1) | DE60043149D1 (ko) |
WO (2) | WO2000045167A2 (ko) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010024783A1 (en) * | 1999-01-29 | 2001-09-27 | Avi Biopharma, Inc. | Non-invasive method for detecting target RNA |
CA2408011A1 (en) | 2000-05-04 | 2001-11-08 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
CA2408746C (en) * | 2000-05-17 | 2010-09-21 | Patrick L. Iversen | Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics |
AU2001286966B2 (en) * | 2000-08-30 | 2007-03-01 | Avi Biopharma, Inc. | Method for analysis of oligonucleotide analogs |
US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
DK2351844T3 (da) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
AU2004263124B2 (en) * | 2003-08-07 | 2009-01-15 | Avi Biopharma, Inc. | Sense antiviral compound and method for treating ssRNA viral infection |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
CA2553104A1 (en) * | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US7807816B2 (en) | 2004-06-28 | 2010-10-05 | University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
ATE510914T1 (de) * | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
BRPI0519690A2 (pt) * | 2004-12-30 | 2009-03-03 | Todd M Hauser | composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos |
ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
US8329668B2 (en) * | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2007103529A2 (en) * | 2006-03-07 | 2007-09-13 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
DK2024499T3 (da) * | 2006-05-10 | 2018-01-29 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske intersubunit-koblinger |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
EP2350281B1 (en) | 2008-10-24 | 2014-05-14 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
CA2746508A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
CA2799501C (en) | 2010-05-28 | 2022-02-15 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
JP5850519B2 (ja) * | 2011-05-09 | 2016-02-03 | ネッパジーン株式会社 | モルフォリノ搭載バブルリポソームを有効成分としてなる筋ジストロフィー治療薬 |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
EA035030B1 (ru) | 2011-11-18 | 2020-04-20 | Сарепта Терапьютикс, Инк. | Модифицированные морфолиновые аналоги олигонуклеотидов |
BR122020016865B1 (pt) | 2013-03-14 | 2022-12-27 | Sarepta Therapeutics, Inc. | Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd) |
CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES |
HUE059843T2 (hu) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exonátugró oligomerkonjugátumok izomdisztrófiára |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009033A1 (en) * | 1989-12-20 | 1991-06-27 | Anti-Gene Development Group | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
DE3650699T2 (de) * | 1985-03-15 | 1999-04-15 | Antivirals Inc | Immunotestmittel für Polynukleotid und Verfahren |
US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5235033A (en) * | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5378841A (en) * | 1989-12-20 | 1995-01-03 | Antivirals Inc. | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5843684A (en) | 1990-06-27 | 1998-12-01 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes |
US5756476A (en) * | 1992-01-14 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell proliferation using antisense oligonucleotides |
HU220969B1 (hu) * | 1993-01-07 | 2002-07-29 | Thomas Jefferson University | A C-MYC-re specifikus antiszensz oligonukleotid alkalmazása simaizomsejtek proliferációjának szabályozásában |
US6323184B1 (en) * | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
WO1995010305A1 (en) * | 1993-10-15 | 1995-04-20 | Thomas Jefferson University | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5981731A (en) | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
CA2126952C (en) * | 1994-06-28 | 2010-12-14 | Sithian Pandian | Probe, kit, and method of amplification for increasing the sensitivity of nucleic acid hybridization assays |
CA2139070C (en) * | 1994-12-23 | 2010-03-30 | Burton W. Blais | Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction |
DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
-
2000
- 2000-01-28 EP EP00911675A patent/EP1173561A2/en not_active Withdrawn
- 2000-01-28 CA CA002360997A patent/CA2360997A1/en not_active Abandoned
- 2000-01-28 WO PCT/US2000/002475 patent/WO2000045167A2/en not_active Application Discontinuation
- 2000-01-28 AU AU33537/00A patent/AU778057B2/en not_active Ceased
- 2000-01-28 KR KR1020017009235A patent/KR20010102992A/ko not_active Application Discontinuation
- 2000-01-28 JP JP2000596368A patent/JP2002535015A/ja active Pending
- 2000-01-28 US US09/493,494 patent/US6365351B1/en not_active Expired - Lifetime
- 2000-01-29 CA CA2359317A patent/CA2359317C/en not_active Expired - Lifetime
- 2000-01-29 KR KR1020017009506A patent/KR100684547B1/ko active IP Right Grant
- 2000-01-29 AT AT00905838T patent/ATE445700T1/de not_active IP Right Cessation
- 2000-01-29 WO PCT/US2000/002331 patent/WO2000044897A1/en active IP Right Grant
- 2000-01-29 DE DE60043149T patent/DE60043149D1/de not_active Expired - Lifetime
- 2000-01-29 AU AU27459/00A patent/AU779128B2/en not_active Expired
- 2000-01-29 JP JP2000596139A patent/JP2002537230A/ja active Pending
- 2000-01-29 EP EP00905838A patent/EP1153129B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009033A1 (en) * | 1989-12-20 | 1991-06-27 | Anti-Gene Development Group | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
Non-Patent Citations (1)
Title |
---|
논문 Journal of Clinical Investigation(Vol. 93, No. 2, 페이지 820-828, 1994 * |
Also Published As
Publication number | Publication date |
---|---|
EP1153129A1 (en) | 2001-11-14 |
WO2000045167A2 (en) | 2000-08-03 |
EP1153129B1 (en) | 2009-10-14 |
CA2359317C (en) | 2014-01-21 |
WO2000044897A1 (en) | 2000-08-03 |
ATE445700T1 (de) | 2009-10-15 |
AU3353700A (en) | 2000-08-18 |
JP2002537230A (ja) | 2002-11-05 |
AU778057B2 (en) | 2004-11-11 |
US6365351B1 (en) | 2002-04-02 |
KR20010101760A (ko) | 2001-11-14 |
JP2002535015A (ja) | 2002-10-22 |
EP1173561A2 (en) | 2002-01-23 |
WO2000045167A3 (en) | 2000-12-21 |
AU2745900A (en) | 2000-08-18 |
AU779128B2 (en) | 2005-01-06 |
CA2360997A1 (en) | 2000-08-03 |
DE60043149D1 (de) | 2009-11-26 |
CA2359317A1 (en) | 2000-08-03 |
KR20010102992A (ko) | 2001-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100684547B1 (ko) | C-myc의 안티센스 표적화에 의한 재협착 치료 방법 | |
US7094765B1 (en) | Antisense restenosis composition and method | |
US20070265215A1 (en) | Antisense restenosis composition and method | |
KR100316205B1 (ko) | 평활근세포의증식을조절하기위한c-myc의안티센스억제 | |
JP3231779B2 (ja) | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
US5656612A (en) | Antisense oligonucleotide modulation of raf gene expression | |
US5919773A (en) | Antisense oligonucleotide modulation of raf gene expression | |
US5985558A (en) | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos | |
US6111094A (en) | Enhanced antisense modulation of ICAM-1 | |
EP0871496B1 (en) | Arteriovenous and venous graft treatments: methods and compositions | |
US6358932B1 (en) | Antisense oligonucleotide inhibition of raf gene expression | |
JPH10500309A (ja) | リボザイムを用いて再狭窄および癌を治療するための方法および組成物 | |
KR100211178B1 (ko) | 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절 | |
WO1999063114A1 (en) | Antisense oligonucleotide modulation of human thymidylate synthase expression | |
WO1997014440A1 (en) | Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia | |
Class et al. | Patent application title: ANTISENSE RESTENOSIS COMPOSITION AND METHOD Inventors: Patrick L. Iversen (Corvallis, OR, US) Dwight D. Weller (Corvallis, OR, US) Assignees: AVI BIOPHARMA, INC. | |
US20030199463A1 (en) | DNA enzyme to inhibit plasminogen activator inhibitor-1 | |
CA2377273A1 (en) | Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof | |
WO2011009082A2 (en) | Compositions comprising human rhbdf1-modulating nucleic acids and methods of use | |
US20060142236A1 (en) | Antisense oligonucleotide modulation of raf gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130128 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140128 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150128 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160126 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170203 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180131 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190131 Year of fee payment: 13 |